MALT lymphoma

This early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…

This phase 2 trial is testing a new approach for adults with stage I-II MALT lymphoma, a slow-growing cancer of the lymph nodes. Participants first receive a very low dose of radiation (4 Gy total) over two days, then take a daily targeted drug called orelabrutinib for up to 6 mo…

This phase 1 trial is testing a combination of two targeted drugs, zanubrutinib and sonrotoclax, in people from underrepresented racial and ethnic groups who have relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to see if this treatment is feasible and safe for …

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…

This study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…

This study tests a drug called mosunetuzumab in 35 people with a rare type of lymphoma (EMZL) who haven't had treatment yet. The drug is given as injections under the skin over several cycles. The goal is to see if it can shrink or eliminate the cancer and to check its safety.

This study tests whether the investigational drug epcoritamab can help people with newly diagnosed marginal zone lymphoma, a slow-growing blood cancer. About 25 adults will receive the drug and be monitored for complete remission after 12 cycles. The goal is to see if this treatm…